iTeos Therapeutics presents preliminary data on Belrestotug + Dostarlimab combo therapy for NSCLC patients

From GlobeNewswire: 2024-08-21 07:18:55

iTeos Therapeutics will present preliminary data from the GALAXIES Lung-201 study at the ESMO Congress on September 13-17, 2024. The study focuses on Belrestotug + Dostarlimab combination therapy for untreated non-small cell lung cancer patients with high PD-L1 levels. The presentation will provide insights into this Phase-II platform study sponsored by GSK. The study aims to evaluate the efficacy of the treatment in locally advanced or metastatic NSCLC patients.

The GALAXIES Lung-201 study results will be presented as a late-breaking session at the ESMO Congress. The study involves a Phase-II platform trial investigating the Belrestotug + Dostarlimab combo in untreated advanced NSCLC patients with high PD-L1 expression. The abstract will be accessible on the ESMO website at 00:05 AM CEST on the day of the presentation.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of a new generation of immunotherapy treatments for cancer patients. The company’s innovative pipeline includes programs targeting immune-suppressive pathways like the TIGIT/CD226 axis and the Adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA, with a research center in Gosselies, Belgium.

Belrestotug (EOS-448/GSK4428859A) is a human monoclonal antibody targeting the TIGIT immunoreceptor, playing a crucial role in suppressing the innate immune response against cancer. The optimized high-affinity antibody aims to enhance the antitumor response through multiple immunomodulatory mechanisms. The therapeutic candidate is being developed in collaboration with GSK for various indications.

For more information, investors and potential investors can visit the “Investors” section on iTeos Therapeutics’ website at www.iteostherapeutics.com. Conversely, media inquiries can be directed to [email protected].



Read more at GlobeNewswire: iTeos Therapeutics kündigt brandaktuelle mündliche